When it comes to innovation in synthetic biology (or “SynBio”), we’re seeing Europe punch above its weight but there remains a disconnect in seeing this translate into commercial value and investment, falling behind other major players, namely the US.
[Translated in English from a tribune published in the French newspaper L’Opinion on October 27th 2022].
The health crisis has demonstrated with a brutality that has shocked – and sometimes bruised – many of our fellow citizens: Europe, and in particular France, has lost control of the supply chain of its health products, particularly of some of its Medicines of Major Therapeutic Interest (MMTI).
In his introductory speech, His Serene Highness Prince Albert II of Monaco stated: “I am especially pleased that the Principality of Monaco is able to welcome your work, support it and contribute to its success. I also welcome the dialogue that has been established between eureKARE and the Scientific Center of Monaco, in particular the opportunity to host one of your studios on its premises, like those you have already set up in various scientific centers across Europe”.
Organized by eureKARE and the Centre Scientifique de Monaco (CMS), SynBio Day, a conference about synthetic biology, took place in mid-October in the Principality of Monaco, giving an opportunity to discuss advances in technologies with tremendous potential.
Following the success of the inaugural 2021 event, SynBio Day 2022 will bring together researchers, industry partners, government representatives and investors to discuss the opportunities and challenges of applying synthetic biology solutions to tackle climate change and benefit our environment.
Luxembourg | France | Belgium
Subscribe to our news to keep in touch
